Apellis Pharmaceuticals Inc. (APLS) has plunged -6.89% at $49.21 in after-hours trading hours on the last check Wednesday. The stock of Apellis (APLS) lost -2.35% to complete the last trading session at $52.85. The price range of the company’s shares was between $52.69 and $54.48. It traded 0.61 million shares, which was below its daily average of 1.07 million shares over 100 days. APLS’s shares have gained by 16.82% in the last five days, while they have added 23.86% in the last month. APLS stock plummeted after announcing a proposed public offering.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
The APLS has made what kind of offering?
As a global biopharmaceutical company, Apellis uses courageous science, creativity, and compassion to deliver life-changing therapies. Known as a pioneer in complementary medicine, Apellis developed the first and only targeted C3 therapy in 15 years. By advancing this science, APLS continues to develop new medicines to treat rare, retinal, and neurological diseases.
Apellis (APLS) has launched an underwritten public offering of $300 million of its common stock.
- APLS is offering all of the shares for sale.
- Further, APLS expects to grant underwriters an option to purchase up to an additional 15% of its shares in the public offering within 30 days of the offering.
- Joint book-running managers for the offering are J.P. Morgan Securities LLC, Goldman Sachs & Co LLC, and Evercore Group LLC.
- Market and other conditions may affect the completion of the offering, and no assurance can be given as to whether it will be completed or what the terms will be.
- A shelf registration statement, automatically effective on January 7, 2020, is being filed with the Securities and Exchange Commission (“SEC”) by Apellis to offer the shares.
APLS came up with encouraging results
- APLS recently presented more detailed results from its Phase 3 DERBY and OAKS studies.
- According to APLS research, pegcetacoplan, an investigational targeted C3 treatment, reduced geographic atrophy (GA) lesion growth.
- The treatment of GA secondary to age-related macular degeneration (AMD), demonstrated a favorable safety profile at month 18.
- In the second quarter of 2022, APLS plans to submit it to the US Food and Drug Administration (FDA) as part of its New Drug Application (NDA).
- With pegcetacoplan, the results showed continuous improvement as time progressed.
What does APLS data indicate?
Based on 18-month results from APLS, pegcetacoplan significantly slows disease progression, which may lead to longer vision preservation. There is an urgent. As a result of the Apellis (APLS) study results, pegcetacoplan looks to be the first treatment available to patients with GA.